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Background: Surgery is often advocated in patients with resectable pulmonary metastases from colorectal cancer
(CRC). Our study aims to evaluate peri-operative chemotherapy in patients with metastastic CRC undergoing
pulmonary metastasectomy.
Methods: Patients treated for CRC who underwent pulmonary metastasectomy by a single surgeon were identified.
Outcome measures included survival, peri-operative complications, radiological and histological evidence of
chemotherapy-induced lung toxicities.
Results: Between 1997 and 2009, 51 eligible patients were identified undergoing a total of 72 pulmonary
resections. Thirty-eight patients received peri-operative chemotherapy, of whom 9 received an additional biological
agent. Five-year overall survival rate was 72% in the whole cohort - 74% and 68% in those who received peri-
operative chemotherapy (CS) and those who underwent surgery alone (S) respectively. Five-year relapse free
survival rate was 31% in the whole cohort - 38% and ≤18% in CS and S groups respectively. Only 8% had disease
progression during neoadjuvant chemotherapy. There were no post-operative deaths. Surgical complications
occurred in only 4% of patients who received pre-operative chemotherapy. There was neither radiological nor
histological evidence of lung toxicity in resected surgical specimens.
Conclusions: Peri-operative chemotherapy can be safely delivered to CRC patients undergoing pulmonary
metastasectomy. Survival in this selected group of patients was favourable.
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Colorectal cancer (CRC) accounts for about 10% of all
cancers worldwide with 1.2 million new cases and over
600,000 deaths in 2008 [1]. Despite a lack of randomised,
prospective data, resection of both hepatic and pulmonary
metastases has become a standard of care for selected
CRC patients [2]. While not all patients benefit from sur-
gery, a recent systematic review found 5-year survival after
complete resection of lung metastases ranged between 40-
68% [3] – higher than expected from use of modern com-
bination chemotherapy in unresected metastatic CRC [4].* Correspondence: ian.chau@rmh.nhs.uk
1Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton,
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reproduction in any medium, provided the orNumerous published series of surgical outcomes have
identified negative prognostic factors including presence
of multiple (i.e. >2) or bilateral metastases [5,6], elevated
pre-thoracotomy carcinoembryonic antigen (CEA) level
(>5 ng/mL) [7], largest lesion > 30 mm [8], local nodal in-
volvement [9,10], and higher stage of primary tumour [6]
yet these have not routinely been adopted into the clinical
decision-making model due to the heterogeneous and
contradicting nature of the published literature.
Peri-operative chemotherapy has been incorporated
into the clinical management of resectable liver metasta-
ses following the encouraging results of the European
Organisation for Research and Treatment of Cancer
(EORTC) 40983 study using peri-operative chemother-
apy [11]. Targeted agents such as bevacizumab andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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liver-only metastatic disease [12-14]. Despite advances
made in peri-operative treatment of resectable hepatic
metastases, there remains a relative paucity of data
regarding its role in pulmonary metastasectomy, and any
resulting toxicity. Previously we reported on 11 patients
from our joint-institution (Royal Marsden/Royal Brompton
Hospitals) series [15]. In this current study, we report on
an expanded cohort treated until March 2009 as well as
evaluating the role of pre-operative positive emission
tomography (PET) and examining for evidence of
chemotherapy-induced pulmonary toxicity.
Methods
The study was approved by our Institutional Review Board
(CCR SE3343). Patients ≥18 years of age with a histo-
logical diagnosis of colorectal adenocarcinoma who
underwent a curative-intent pulmonary metastasectomy
were deemed eligible. Patients undergoing oncological
treatment at the Royal Marsden Hospital (RMH) were
identified from a list of pulmonary metastases resections
performed at the Royal Brompton Hospital (RBH) by a
single surgeon (GL) between January 1997 and March
2009. All information was collated from patient records at
both RMH and RBH. Based on the RMH GI unit guide-
lines, CRC patients were reviewed in a multidisciplinary
meeting, and selected for perioperative chemotherapy if
disease-free interval <2 years and the nature of the pul-
monary nodules was deemed to be malignant. Data were
collected on age, gender, primary tumour site and date of
primary tumour resection, adjuvant therapy related to the
primary tumour, date of lung metastases diagnosis,
disease-free interval (DFI) (calculated from the date of pri-
mary colorectal tumour resection to date of diagnosis of
first lung metastasis), pulmonary surgery, relapse site and
date of death or last follow up. Details of pulmonary sur-
gery, peri-operative chemotherapy related to pulmonary
metastases, including response, toxicities and complica-
tions, as well as pre-operative CEA levels were recorded.
Following pulmonary resection, standard follow-up at this
institution consisted of 3-monthly clinical review and
CEA levels for the first year then 6-monthly reviews plus
CEA levels thereafter as well as 6–12 monthly imaging
with computed tomography (CT) scan.
Patients were selected for pulmonary metastasectomy
based on the following criteria: 1) primary tumour con-
trolled; 2) the only identifiable sites of metastatic disease
being lung or liver or both; 3) disease stability in terms
of number of lesions confirmed on interval scans; 4)
complete resection of all deposits feasible and 5) patient
fit for planned procedure [2]. Details of surgical ap-
proach are outlined in Appendix A.
All those undergoing neoadjuvant chemotherapy
underwent a baseline and pre-operative CT scan.However 2 patients had scans externally with no report
available. A documented reduction in size of lesions was
recorded. Standard radiological response criteria such as
RECIST [16] were not possible to use due to small size
(often sub-centimetre) of pulmonary metastases.
Haematological and biochemical toxicities were graded
according to the National Cancer Institute Common Ter-
minology Criteria for Adverse Events version 3.0
(CTCAEv3.0). Clinical toxicities were also graded, based
on documented findings and the treatment required. Evi-
dence of lung toxicities such as pneumonitis and pulmon-
ary fibrosis, as documented on CT scan, was also recorded.
Resected paraffin-embedded lung tissue specimens were
examined by two specialised pulmonary pathologists
(AGN and KW), who were blinded to all clinical informa-
tion concerning chemotherapy. Samples were assessed for
viable tumour. Non-tumour lung tissue from each speci-
men was also assessed for evidence of chemotherapy-
related toxicity including pulmonary eosinophilia, intersti-
tial fibrosis and/or inflammation unrelated to the locale of
the tumour. These findings were subsequently correlated
with clinical data to evaluate the possible role of neoadju-
vant chemotherapy in lung toxicity.
Surgical approach
The main aim was complete resection of all deposits
with clear margins, whilst preserving as much lung par-
enchyma as possible. Pre-operative biopsy of suspect
lesions was not performed. All lesions visible on pre-
operative CT scan were recorded and mapped preopera-
tively. Lesions which had achieved a complete
radiological response from neoadjuvant chemotherapy
and were no longer visible were not resected. Muscle-
sparing, limited postero-lateral thoracotomy was the
most utilised approach. Bilateral disease was resected by
staged bilateral thoracotomies 4-6 weeks apart, or rarely
by median sternotomy and synchronous bilateral resec-
tion. The use of double-lumen endotracheal tubes
allowed single lung anaesthesia, with the operated lung
being collapsed during the procedure. Following removal
of all known lesions, palpation was used to identify add-
itional lesions not detected on CT scan. In our experi-
ence, on average 25% more nodules were discovered this
way, hence Video Assisted Thoracoscopy is rarely used
in our metastasectomy practice. A wide range of resec-
tion techniques were used. Small nodules were removed
by “precision resection”, using diathermy spatula or laser
beam, with a sphere of surrounding healthy lung paren-
chyma to ensure clearance. Deeper parenchymal lesions,
underwent localised resection via an anatomical sub-
segmental to ligate individual feeding vessels and bron-
chi. Sizeable tumours involving larger hilar structures
were removed using anatomical segmentectomy or lob-
ectomy, always in combination with nodal dissection at
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fied. A combination of various techniques is often used
in the same patient when multiple deposits are present.
Since a lobectomy with a systematic nodal dissection
is the accepted minimum resection for primary lung
cancer, distinguishing a new lung primary adenocarcin-
oma from a solitary colonic metastasis was crucial, in
planning the appropriate resection. Given that up to
80% of primary lung adenocarcinomas stain positive for
Thyroid Transcription Factor -1 (TTF-1), we regularly
used intraoperative immunohistochemistry for TTF-1 onTable 1 Patient characteristics
Patient characteristics Patients who received
peri-operative chemothera
Number of patients 38
Number of pulmonary resections 56












Lung + Omentum 1
Adjuvant chemotherapy for primary CRC
Yes 24
With neoadjuvant CRT 3
With neoadjuvant chemo + CRT 3
With Adjuvant RT 0
No 8
Site of first metastases
Lung only 29





Recorded 35 (49 resections)
Not Recorded 3 (7 resections)
>institutional ULN 7 (8 resections)
Median CEA (range) 2 μg/dl (1–1094)
Numbers in table refer to number of patients unless otherwise specified.
*either prior to neoadjuvant chemotherapy or prior to surgery if no neoadjuvant chfrozen section specimens to make this distinction. In
February 2010 we started using a 1318 nm lung laser de-
vice, and laser assisted lung resection was now routinely
used in all metastasectomy patients in our practice.
Statistical considerations
The primary endpoint of the study was overall survival
(OS). Secondary endpoints include relapse-free survival
(RFS), response to neoadjuvant chemotherapy where ap-
plicable and toxicity. Overall survival was measured


























10 (12 resections) 45 (61 resections)
3 (4 resections) 6 (11 resections)
2 (2 resections) 9 (10 resections)
1.5 μg/dl (<1-10) 2 μg/dl (<1-1094)
emotherapy given.
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cause and censored at last follow-up. RFS was measured
from date of initial pulmonary surgery to date of relapse,
death from any cause or date of last follow-up. RFS and
OS were estimated using the Kaplan Meier method [17].
Univariate log-rank analyses were performed to assess the
impact of clinico-pathological factors on survival. Multivari-
ate Cox regression analysis was only performed if >1 factor
were found to be significant (p <0.05). Factors included
were elevated pre-treatment CEA (>institutional upper limit
of normal), number of pulmonary metastases (solitary ver-
sus multiple), largest metastasis (≥30 mm versus <30 mm),
involvement of resected thoracic lymph nodes, disease-free
interval (<12 months versus ≥12 months), PET avidity of
lung lesions (positive versus negative) and peri-operative
chemotherapy (peri-operative cytotoxic drugs versus cyto-
toxic drugs plus a targeted agent versus surgery alone). No
formal statistical comparison of toxicities or complications
was performed due to small numbers of events.
All analyses were performed using SPSS (PASW)
version 18.
Results
Fifty-one eligible patients underwent 72 curative resec-
tions for pulmonary metastases. Table 1 shows the base-





Timing of pre-thoracotomy PET
Before neoadjuvant chemotherapy 16
After neoadjuvant chemotherapy 12
No neoadjuvant chemotherapy 20
CT identified metastases
Median number (range) 1 (1–6)
PET identified metastases
Median number FDG avid (range) 1(1–6)
Histologically identified metastases#
Median number (range) 1 (1–6)
Median size of largest nodule (range) 15 mm (5–60)
Concordance rates on number of metastases+
CT + PET 34 (71)
CT + Histology 28 (61)
PET + Histology 33 (72)
CT + PET + Histology 26 (57)
*2 patients had FDG-avid lung lesions prior to one lung resection but no FDG avid
#Histology obtained at time of resection. All lesions considered involved had viable
+histology not available on 1 PET positive patient, and 2 patients who did not haveour cohort, 38 (75%) received neoadjuvant and/or adju-
vant chemotherapy relating to their pulmonary resection.
In those with no metastatic disease at diagnosis, the me-
dian DFI was 24.1 months (range 2.8 to 64.1) for the
whole cohort - 20.5 months (range 11.7 to 64.1) in the
peri-operative chemotherapy group (CS) and 27.5 months
(range 2.8 to 52.8) in the surgery-alone group (S). How-
ever, 11/38 (29%) patients in the CS group presented with
synchronous metastases at the time of diagnosis.
Forty-five patients had CEA levels performed pre-
thoracotomy, with an elevated result in only 9 patients.
18FDG-PET was performed in 45 patients with only 8 PET
scans demonstrating no FDG-avidity in the lung lesions.
The timing of the PET scan did not affect FDG-avidity,
even in those undergoing neoadjuvant chemotherapy.
Table 2 shows the comparisons among CT, PET and sub-
sequent histology. Concordance with number of con-
firmed pulmonary metastases diagnosed histologically was
higher in PET than CT (72% versus 61%) for those with
FDG-avid lesions. The median size of the largest lesion
was higher in the PET positive group compared to PET
negative group (15 mm versus 8 mm respectively).
Chemotherapy
Of the 38 patients (75%) who underwent peri-operative
systemic therapy, 36 received it with their initialPET negative No PET done
n (%) n (%)
8 (18) 6 (12)




2 (1–3) 2 (1–11)
- -
2 (1–4) 1 (1–12)
8 mm (3–15) 15 mm (2–25)
- -
4 (50) 10 (71)
- -
- -
lung lesions prior to a subsequent lung resection.
tumour.
a PET.
Table 3 Details of systemic chemotherapy
Patients who received
chemotherapy
(n= 38 patients undergoing
56 resections)
Timing of treatment
Chemotherapy plus targeted agent n= 11 resections (in 9 patients)
Neoadjuvant plus adjuvant 7 (64%)
Neoadjuvant alone 4 (36%)
Adjuvant alone 0
Chemotherapy alone n= 38 resections (in 29 patients)
Neoadjuvant plus adjuvant 15 (39%)
Neoadjuvant alone 13 (34%)
Adjuvant alone 10 (26%)
None* n= 7 resections
Type of systemic treatment









Number of cycles Median (range)
Pre-operative 4 (2–12)
Targeted agents 6 (4–12)
Chemo alone 4 (2–8)
Post-operative 5 (2–12)
Targeted agents 6 (4–12)
Chemo alone 4 (2–12)
Chemotherapy-related complications





G3/4 Chest pain 2
G3 VTE (DVT) 1







Table 3 Details of systemic chemotherapy (Continued)




VTE (pulmonary embolism) 1
Numbers in table refer to number of resections unless otherwise specified.
*7 resections occurred where patients received no chemotherapy, but had
received for a prior or subsequent resection.
VTE venous thromboembolism, DVT deep vein thrombosis.
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with subsequent resections. Table 3 shows details of
peri-operative chemotherapy. Nine patients received tar-
geted biological agents combined with neoadjuvant
chemotherapy. All targeted biological treatments were
administered in combination with an oxaliplatin or
irinotecan-based chemotherapy doublet. Post-operative
chemotherapy plus targeted therapy was given to all
patients receiving bevacizumab and 1 patient who
received neoadjuvant cetuximab. In this cohort of 38
patients, chemotherapy was delivered in a total of 49
resections; most commonly peri-operatively (n = 22
resections), with neoadjuvant alone given in 17 resec-
tions and adjuvant alone after 10 resections. Seven
patients who underwent multiple pulmonary resections
received no systemic peri-operative treatment for at least
1 of these resections. The median number of chemother-
apy cycles administered was 4 (range 2–12) pre-
operatively and 5 (range 2–12) post-operatively. Of 30
patients who received neoadjuvant chemotherapy, 8
(27%) developed treatment-related complications (9
events). Post-operative chemotherapy-related complica-
tions occurred more frequently, in 14 patients undergo-
ing adjuvant chemotherapy (54%, 19 events).
None of the CT scans performed following chemotherapy
demonstrated fibrotic changes or pneumonitis suggestive of
chemotherapy-related lung toxicity. Metastatic colorectal
adenocarcinoma was confirmed on independent histological
review in all cases with no histological complete responses
(ie tumour necrosis or fibrosis in the absence of viable
tumour) seen. Histopathological evaluation also demon-
strated no evidence of chemotherapy-related changes to the
non-cancerous lung parenchyma in any cases.
Surgical procedures
Table 4 shows surgery details including type of resection,
metastases removed, lymph node dissection, time from
last dose of neoadjuvant treatment to surgery and surgical
complications. All pulmonary resections were R0
(complete macro- and microscopic resection). Twelve
patients had bilateral sequential resections, with no
chemotherapy administered between. Median time to sur-
gery after last dose of neoadjuvant vascular endothelial
Table 4 Details of surgery and surgical complications
Details of surgical resections Peri-operative chemotherapy Surgery alone Total cohort
n = 56 resections
(38 patients)
n = 16 resections
(13 patients)
n = 72 resections
(51 patients)
Type of resection
Wedge 37 10 47
Segmental 8 2 10
Lobectomy 8 4 12
Pneumonectomy 1 0 1
Not recorded 2 0 2
Metastases removed
Solitary 16 4 20
Multiple 38 12 50
Unknown 2 0 2
Median size (range) 14.5 mm (2–60) 15 mm (4–25) 15 mm (2–60)
Lymph node dissection
Yes 22 5 27
Positive histology 4/22 (18%) 1/5 (20%) 5/27 (19%)
No 31 10 41
Unknown 3 1 4
Time from last dose of neoadjuvant treatment to surgery Median days (range)
Any treatment 48.5 (14–207)
Chemotherapy + 37 (25–85)
VEGF inhibitor
Surgical Complications* 3/68 (4%) 5/16 (31%) 8/84 (9%)
Prolonged air leak 3 0 3
Haemorrhage** 0 1 1
CVA 0 1 1
Cardiac Arrhythmia (fast AF) 0 1 1
Small bowel ileus or obstruction 0 2 2
Numbers in table refer to number of resections unless otherwise specified.
*Surgical complications were evaluated in all operations performed, hence the bilateral sequential resections being counted as separate events and the total
n = 86, not 72.
**The patient was fully anticoagulated.
CRC colorectal cancer, CRT chemoradiation, RT radiotherapy, CEA carcinoembryonic antigen, ULN upper limit of normal, VEGF vascular endothelial growth factor,
CVA cerebrovascular Accident, AF atrial Fibrillation.
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was 37 days (range 25–85), whereas for all other neoadju-
vant treatment median time to surgery was 48.5 days
(range 14–207); the 207 day delay was in a patient who
had significant post-operative complications from original
bowel surgery. The median number of metastasis removed
was 2.5 (range 1–19). Median metastasis size was 15 mm
(range 2 to 60 mm). Surgical complications were uncom-
mon (Table 4). Only 4% of patients undergoing pre-
operative chemotherapy experienced surgical complica-
tions. Twelve patients also underwent hepatic metasta-
sectomy during the course of their treatment.Efficacy
Median follow up for the entire cohort was 60 months.
The median OS in the entire cohort was 77 months
(95% confidence interval [CI]: 55-99 months) and 5-year
survival rate was 72% (95% CI: 55-83%). Eighteen
patients remained disease free after initial resection.
Five-year RFS for the entire cohort was 31% (95% CI:
18-45%). Figure 1 shows the OS and RFS for entire co-
hort. Five-year OS rates were 74% (95% CI: 53-86%) and
68% (95%: CI 35-87%) in CS and S groups respectively.
Five-year RFS rates were 38% (95% CI: 22-54%) and




























Figure 1 Overall and relapse free survival for whole cohort.
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groups. A reduction in tumour size was seen in 21
patients (undergoing 23 of 39 resections - 62%) where
neoadjuvant chemotherapy was administered. In a fur-
ther 10 patients (11 resections or 30%), stable disease
was seen on pre-thoractomy imaging after neoadjuvant
treatment, with 3 incidents of disease progression. Thus,
the disease control rate from neoadjuvant chemotherapy
was 92%. Table 5 summarises the efficacy outcomes.
Figure 3 shows details of relapse and further treatment.
Prognostic Factors
In an univariate analysis, only positive lymph node in-
volvement was significant for survival (p = 0.022), how-
ever only 19 patients had lymph node resection at the
time of pulmonary resection. All other factors assessed
were non-significant and hence multivariate analysis was
not performed.
With respect to RFS, no prognostic factors were found
to be significant in univariate analyses. However, there
was a trend towards improved RFS with chemotherapy
alone compared to surgery alone or chemotherapy plus
a targeted agent (p = 0.058).
Discussion
This study focused on the effects of peri-operative
chemotherapy in the setting of pulmonary resection for
colorectal lung metastases. We believe this is the first
dedicated published series on peri-operative chemother-
apy. The absolute 5-year survival rate was higher in the
CS group compared with S group (74% versus 68%) as
well as 5-year RFS (38% versus ≤18%) despite a shorterDFI. Lymph node involvement was the only significant
prognostic factor found in our cohort but only in uni-
variate analysis. The numbers were too small to compare
lymph node involvement between the perioperative
chemo vs no chemo groups or to perform a multivariate
analysis. Also, the more recent procedures almost rou-
tinely involved lymph node resection whereas earlier
procedures did not, which could be impacted on by nu-
merous confounding factors. Toxicity of chemotherapy
was manageable with no post-operative deaths and only
a 4% surgical complication rate observed in the chemo-
therapy group. Neoadjuvant chemotherapy and targeted
agents did not cause any evidence of pulmonary toxicity,
either radiologically or histologically. FDG-PET scan-
ning, also specifically evaluated for the first time in our
series, provides higher concordance with the number of
histologically proven metastases present than CT when
PET-avid lesions are present (72% versus 61%).
Published series of pulmonary metastasectomy have
included variable numbers of patients who received sys-
temic peri-operative treatment but detailed outcomes of
these subgroups have not been specifically reported. In a
systematic review of 11 retrospective studies including
1307 patients [3], 8 of the 11 studies reported the use of
neoadjuvant or adjuvant chemotherapy but discussion of
toxicity, response, details of the regimen were consist-
ently lacking. Two reports within the review, and two
further published series have evaluated peri-operative
chemotherapy as a prognostic factor. Saito et al [18].
(n = 165) and Lee et al [7]. (n = 59) both found adminis-
tration of peri-operative chemotherapy to be non-
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Figure 2 A Overall survival by treatment group; 2B Relapse free survival by treatment group.
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patients receiving post-operative chemotherapy (83.5
versus 57.1%) yet 5-year disease-free survival was similar
(45.8% versus 46.9%), though in this small cohort, nei-
ther was statistically significant (p = 0.397 and 0.754 re-
spectively) [19]. A larger study of 315 patients by
Kanemitsu et al [20]. reported 27.2% receiving ‘adjuvant
chemoradiotherapy’. Univariate analysis demonstrated a
significant benefit in undergoing adjuvant therapy (Haz-
ard ratio for death at 3 years 0.69, 95% CI 0.49-0.98;
p = 0.037) with a non-significant trend towards reductionin death at 3 years in multivariate analysis (HR 0.71, 95%
CI 0.49-1.03; p = 0.068).
The 5-year OS of 72% in our cohort was higher than
other published series. The recent systematic review
reported a median 5-year OS of only 39.6% (range: 24-56%)
for R0 resected patients [21]. Our OS was promising and
the low morbidity and mortality we reported supports the
use of pulmonary resection and peri-operative chemother-
apy as a treatment modality. With our 5-year RFS of 31%
after initial resection and 3 additional patients being ren-
dered disease-free after subsequent resections, pulmonary
Figure 3 Outcomes of pulmonary resections.
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Table 5 Summary of efficacy results
Total cohort Peri-operative chemotherapy Surgery alone
n= 51 n=38 n=13
Number of patients 51 38 13
Disease-free interval (range) 24.1 months 20.5 months 27.5 months
(2.8-64.1) (11.7-64.1) (2.8-52.8)
Overall survival
Median (95% CI) 77 months (55–99) 91 months (61–121) 67 months (39–96)
3-year (95% CI) 86% (72–93) 85% (68–93) 87% (56–96)
5-year (95% CI) 72% (55–83) 74% (54–86) 68% (35–87)
Relapse free survival
Median (95% CI) 29 months (18–39) 30 months (0–68) 21 months (13–30)
3-year (95% CI) 42% (28–55) 46% (29–61) 38% (12–56)
5-year (95% CI) 31% (18–45) 33% (22–54) ≤18%*
Response to neoadjuvant chemotherapy
n= 39 resections
Complete response 0
Tumour reduction 23 (62%)
Stable disease 11 (30%)
Disease control 34 (92%)
Tumour progression 3 (8%)
No scans available 2
*Not estimable as no events occurred at year 5 and only 1 patient left at risk at year 4 where RFS was estimated at 18%.
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resection in a small number of patients is also a feasible
option.
Neoadjuvant chemotherapy also has the advantage of
assessing in vivo tumour response and overall course of
the disease as well as potentially downsizing lesions.
Whilst we acknowledge that the majority of lung lesions in
this study are not evaluable by RECIST due to small size, a
reduction in radiological tumour size was documented in
62% of resections where neoadjuvant chemotherapy was
administered, with an additional 30% having stable disease.
Indeed, although the presence of necrosis and, to a lesser
extent, fibrosis are features seen in metastatic colorectal
carcinoma, the extent of these changes being up to 80%
likely reflects partial response to chemotherapy prior to
surgery in some cases. Progression was seen in only a
small minority (8%) during neoadjuvant therapy. Obvi-
ously, due to selection bias, we recognise that the cohort
of patients who progressed, becoming unresectable, were
not captured in this study nor did any lesions require
downsizing prior to consideration of resection. However,
this response was similar to published response rates in
metastatic CRC of 36-66% [22-24].
DFI following curative resection of the primary has
been described as a possible prognostic determinant. In
the CS group, DFI was shorter than in the S group,suggesting that those with a shorter DFI are being trea-
ted more aggressively. Despite the slightly shorter DFI in
this group (20.5 months versus 27.5 months, p = 0.277),
the absolute 5-year OS was higher (74% vs. 68%).
This study demonstrates that chemotherapy toxicity
appears manageable in this population. Pfannschmidt’s
2010 systematic review reported a 0–2.4% post-operative
mortality, consistent with our observation of no surgery-
related deaths [3]. Acute surgical complications were
observed less in the chemotherapy group in our study (3
events in 68 resections versus 5 events in 16 resections
for surgery alone). Neoadjuvant chemotherapy was bet-
ter tolerated than adjuvant chemotherapy with fewer
recorded toxicities (reported in 27% versus 54% of
patients). This difference in toxicity pre- and post-
surgery is consistent with reports in operable rectal and
gastric cancers where neoadjuvant and adjuvant chemo-
therapy have been evaluated [25-27]. Of interest, in
patients who received targeted therapy, only 2 complica-
tions occurred. A patient receiving neoadjuvant sunitinib
plus FOLFIRI (within the context of a phase I dose-
escalation study) developed grade 4 neutropenia pre-
operatively and a patient receiving FOLFIRI chemother-
apy plus cetuximab had a prolonged air-leak. None of
the toxicities or surgical complications occurred in the 6
patients receiving chemotherapy plus bevacizumab with
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ment and surgery of 37 days, despite the widely pub-
lished wound-healing, bleeding and thromboembolic
complications known to occur with bevacizumab. There
was no radiological evidence of chemotherapy-related
pulmonary toxicity and histological evaluation of the
resected tissue demonstrated no evidence of toxic
changes to non-tumour lung parenchyma. This is re-
assuring, and certainly in contrast to that of neoadjuvant
chemotherapy in the setting of liver resection, where it
is well documented that irinotecan can cause steatohe-
patitis and oxaliplatin is associated with sinusoidal ob-
struction syndrome [28]. There are currently no data on
chemotherapy-induced lung toxicity seen histologically
within the context of resectable CRC pulmonary metas-
tases and our report represents first preliminary evi-
dence demonstrating no significant histological damage
is detected following CRC chemotherapy.
CT is not highly accurate in differentiating malignant
from benign pulmonary nodules, hence many benign
lesions are removed in pulmonary metastasectomy. FDG-
PET is used routinely to confirm a single metastatic site of
disease prior to resection however may assist in further de-
lineating malignant involvement of pulmonary lesions.
Concordance of FDG-PET with histological involvement
of pulmonary nodules has not previously been assessed. In
patients undergoing neoadjuvant chemotherapy, the tim-
ing of preoperative PET varied in our cohort, yet adminis-
tration of chemotherapy did not impact on FDG-avidity of
the lesions. In PET-positive patients, we observed a higher
concordance between number of lesions with positive hist-
ology and PET than CT. These concordance rates were ex-
ploratory and hence only described in absolute values, the
limited sample size precluded any formal statistical testing.
With further evaluation, this may have important conse-
quences on the decision of which lesions to resect at sur-
gery in addition to excluding extrapulmonary disease.
The most important limitation of our study was the se-
lectivity of our approach. Included patients needed to have
resectable pulmonary metastases, physical fitness for lung
resection and no progression during neoadjuvant chemo-
therapy to the extent of being denied surgery. In patients
who had significant co-morbidities, radiofrequency abla-
tion might have been utilised as an alternative. High usage
of PET scanning in our study ensured that patients with
extra-thoracic non-hepatic metastases were excluded from
pulmonary resection. As an indication, our institution
commenced 670 patients on first line chemotherapy for
metastatic CRC between 2000 and 2008 (equivalent of
about 80 patients per year) [29].
Conclusions
To our knowledge, this is the largest study of patients
dedicated to evaluating peri-operative chemotherapy andtargeted therapy in the setting of pulmonary resection
for CRC metastases. The role of pulmonary metaste-
ctomy has not been validated in a prospective rando-
mised trial to date however based on published data, has
been standard practice for selected patients at our intui-
tions for more than a decade. The inclusion of peri-
operative chemotherapy in the management paradigm
for these patients has not been associated with add-
itional specific pulmonary toxicity and a promising
relapse-free and overall survival was observed.
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